Large and Innovative Pipeline
The active pain pipeline is
populated by 796 products across all stages of development, which exhibit a
highly diverse range of molecular targets. GBI Research’s analyses identified
122 first-in-class programs in active development, constituting 13.6% of the
pipeline and acting on 65 first-in-class molecular targets, indicating a high
degree of innovation. This is in stark contrast to the pain therapeutics
market, which has been largely characterized by only incremental product
innovation over the last decade, as most market segments continue to be
dominated by long-established active pharmaceutical ingredients and the
concomitant mechanisms of action. Moderate-to-severe pain continues to be
dominated by opioids that are increasingly being reformulated to offer
abuse-resistance, while mild pain is effectively treated with Non-Steroidal
Anti-Inflammatory Drugs (NSAID). However, significant unmet needs remain, as
chronic pain and some neuropathic pain subtypes do not respond well to existing
therapies, which are not adequate to treat associated hypersensitization and do
not align to the underlying molecular pathophysiological profile.
Browse
Full Report With TOC @ http://www.radiantinsights.com/research/frontier-pharma-pain-identifying-and-commercializing-first-in-class-innovation
Despite being mostly distributed
in the early stages of development, first-in-class innovation is particularly
concentrated on novel molecular targets that are aligned to the central sensitization
associated with neuropathic pain, which is arguably the most debilitating and
difficult-to-treat type of chronic pain. This gives them the potential to
transform the future market by expanding the range of drug classes.
Highly Diversified Range of
Innovative Programs in Early Pipeline and in Granted Patents
Pain
is a complex and multifaceted disorder with a complex interplay between
different pathological processes, and different pain subtypes exhibit distinct
underlying etiologies and pathophysiologies. While technological advances and
extensive research efforts have furthered the understanding of these complex
underpinnings, gaps remain. However, these insights have translated into the
expanding pool of novel therapeutic targets, as reflected by the highly
innovative pipeline. GBI Research’s proprietary analysis shows that
early-stage, first-in-class programs exhibit a higher level of diversity with
respect to novel therapeutic targets. The significant diversity in terms of
targets is a reflection of the complex underpinnings of distinct pain subtypes.
Although the pipeline continues to feature established therapies, the range of
mechanisms of action employed by novel compounds is extremely diverse, with the
vast majority residing in the Preclinical stage. This innovation and diversity
is maintained throughout the pipeline from early- to late-stage development,
although the degree of innovation diminishes from Phase II. Additionally,
although NSAIDs and opioids remain the cornerstone of pain treatment,
About Radiant
Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
Contact:
Michelle
Thoras
Corporate
Sales Specialist, USA
Radiant
Insights, Inc
Phone:
1-415-349-0054
Toll
Free: 1-888-202-9519
No comments:
Post a Comment